The Tat protein of human immunodeficiency virus 1 (HIV-1) can enter cells efficiently when added exogenously in tissue culture. To assess if Tat can carry other molecules into cells, we chemically cross-linked Tat peptides (residues 1-72 or 37-72) to 3-galactosidase, horseradish peroxidase, RNase A, and domain Ill ofPseudomonas exotoxin A (PE) and monitored uptake colorimetrically or by cytotoxicity. The Tat chimeras were effective on all cell types tested, with staining showing uptake into all cells in each experiment. In mice, treatment with Tat-f-galactosidase chimeras resulted in delivery to several tissues, with high levels in heart, liver, and spleen, low-to-moderate levels in lung and skeletal muscle, and little or no activity in kidney and brain. The primary target within these tissues was the cells surrounding the blood vessels, suggesting endothelial cells, Kupffer cells, and/or splenic macrophages.
endothelial cells, Kupffer cells, and/or splenic macrophages.
Tat-mediated uptake may allow the therapeutic delivery of macromolecules previously thought to be impermeable to living cells.
The potential for intracellular therapeutic use of proteins, peptides, and oligonucleotides has been limited by the impermeable nature of the cell membrane to these compounds. A wide variety of methods have been proposed for the delivery of proteins and other macromolecules into living cells for either experimental or therapeutic uses, including microinjection, scrape loading, electroporation, liposomes (1) (2) (3) (4) (5) (6) (7) , bacterial toxins (8) (9) (10) , and receptor-mediated endocytosis (11) (12) (13) (14) (15) (16) . Most of these methods are either inefficient or time-consuming, cause appreciable cell death, or result in uptake into intracellular vesicles without efficient cytoplasmic delivery. Several approaches (15) (16) (17) (18) rely on binding of macromolecules to the cell surface, followed by internalization via the endocytic route. However, since proteins that have entered this pathway remain enclosed within lipid vesicles, they do not have access to the cell cytoplasm, most typically the target environment. It seems reasonable to assume that the escape from endocytic vesicles is the ratelimiting step in achieving true cellular delivery, yet many assays fail to measure this.
Recently the Tat protein from human immunodeficiency virus 1 (HIV-1) was shown to enter cells when added exogenously (19, 20) . Tat protein can simply be added to medium at concentrations as low as 1 nM, and biological responses can be detected. Since the assay for this process was the transactivation of a transfected reporter gene, activity reflects those molecules that had been targeted to the nucleus, presumably after cytoplasmic delivery. The mechanism by which Tat traverses a membrane and the precise intracellular location of this event remain unclear. However, Tat binds efficiently to cells, with >107 sites per cell and then is internalized by an adsorptive endocytosis process (20) . In characterizing the uptake process using iodinated Tat, Mann and Frankel (20) observed that only 3% of the Tat became
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cell-associated. In contrast, using Tat that was metabolically labeled with [35S]methionine, we found that >60% of the Tat became cell-associated. The added radioactivity was rapidly converted into a trypsin-insensitive form, indicating that it had been internalized. We estimate that it is possible to deliver 107 molecules per cell into a trypsin-insensitive form.
Experiments in our laboratory and from Frankel's group have shown that fluorescently tagged Tat protein becomes cell surface-associated and is internalized into punctate structures that resemble endosomes/lysosomes; eventually label becomes apparent both cytoplasmically and in the nucleus (20) . The basic RNA binding domain of Tat has been implicated in mediating at least the cell surface binding of Tat; indeed, uptake/activation can be blocked by incubation with soluble polyanions, including heparin and dextran sulfate (20) . To obtain optimal Tat-dependent transactivation, Frankel and Pabo (19) added the lysosomotropic agent chloroquine and showed subsequently that this treatment reduced degradation of the Tat protein.
The apparent efficiency with which Tat is able to enter cells raised the possibility of utilizing Tat to deliver heterologous macromolecules into cells. Here we show that Tat peptides conjugated to heterologous proteins can confer cellular delivery to these "cargo" proteins. Delivery is independent of cell type, has been successfully applied to four different cargo proteins, and has been shown unambiguously to mediate cytoplasmic delivery. Preliminary in vivo experiments confirm that this system may allow the therapeutic use of proteins/peptides with intracellular targets.
MATERIALS AND METHODS
Preparation of Tat Peptides. Tat-(1-72) was expressed in Escherichia coli by using a T7 expression vector (21) and was purified by sequential chromatography steps on Q-Sepharose (Pharmacia), gel filtration on an A.5M agarose column in 6.0 M guanidine hydrochloride, and reverse-phase HPLC on a C4 column (Vydac). The product was >95% pure as judged by analysis by SDS/PAGE. Tat-(37-72) (CFITKALGISYGRK-KRRQRRRPPQGSQTHQVSLSKQ in single-letter amino acid code) was synthesized on an Applied Biosystems 430A synthesizer following the manufacturer's recommended procedures and purified by reverse-phase HPLC; integrity was verified by mass spectrometry.
Chemical Conjugation. /3Galactosidase (Sigma) was dissolved in phosphate-buffered saline (PBS) at 25 mg/ml and treated with iodoacetamide (final concentration, 0.37 mg/ml) for 60 min at 23°C. The product was desalted on a G-25 column (Pharmacia) in PBS and concentrated to 32 mg/ml in a Centricon 10 concentrator (Amicon). 
RESULTS AND DISCUSSION
Since the Tat protein from HIV-1 can enter cells when added extracellularly, we decided to test if Tat could be used as a carrier to deliver heterologous molecules into cells. Chemically crosslinked conjugates of the enzymes 3-galactosidase and HRP were prepared with either Tat-(1-72) or Tat-(37-72).
Truncated Tat-(37-72) was selected because it retains the basic domain implicated in binding/uptake and lacks the cysteine-rich region of Tat (residues 22-37) that has complicated the handling and analysis ofpeptides/conjugates (B.P., unpublished results). Tat-(37-72) retains the cellular delivery function of Tat-(1-72) (see below). The degree of conjugation was monitored by SDS/PAGE and adjusted so that only one or two peptides per f3galactosidase tetramer or one peptide per HRP molecule was incorporated. Under these conditions the conjugates were shown to retain essentially full enzymatic activity.
Samples were then applied to cells under standard tissue culture conditions and evaluated for uptake by histology using chromogenic enzyme substrates. Even at the highest concentration tested (20 ,ug/ml) there was no staining with either control enzyme lacking the Tat peptides ( Fig. 1 a and  d) . HRP has been used by others as a fluid-phase uptake marker, but in these experiments very high concentrations (>200 ,g/ml) have typically been used (22) , and in our hands similar experiments result in staining levels considerably lower than those described below. Separate addition of the enzyme with noncovalently linked Tat peptides did not result in cell staining (data not shown). Cells treated with Tat conjugates consistently revealed intense cellular staining (Fig. 1 b, c, e, and f) . Staining was predominantly surfaceassociated after short, 0-to 20-min incubation periods with progressive accumulation in intracellular staining over 30 min to 6 hr. Incubations of 18 hr yielded highest levels of staining, and subsequent chase periods of up to 24 or 48 hr without conjugate still resulted in detectable intracellular activity with a concomitent decrease in surface staining. A large proportion of the intracellular staining appeared to be punctate, even at late time points, suggestive of endosomes/ lysosomes, but there was significant diffuse cytoplasmic, nuclear, and nucleolar staining in all experiments, especially at higher doses and later time points (Fig. 1 c and f) . The nuclear/nucleolar localization ( Fig. 1 c, h, (Fig. 1i) or Tat-(37-72) (Fig.  lc) , although the reagents prepared with the latter peptide typically possessed improved solubility and storage characteristics. Repeated washing oftreated cells before fixation did not reduce the cell-associated enzyme activity, but mild trypsinization abolished the surface staining. /3Galactosidase activity was also measured quantitatively by using the substrate o-nitrophenyl ,B-D-galactopyranoside.
After overnight incubation with the Tat-f3galactosidase conjugate (40 pg/ml), cells were trypsinized, and trypsinsensitive and -insensitive activities were determined. Typically 5 x 106 molecules of enzyme were bound per cell, and of this material at least 20% was internalized as judged by resistance to trypsin treatment-i.e., 106 molecules per cell. A striking feature of the enzyme delivery was that all cells in each experiment were stained and that uptake could be demonstrated in all cells tested (including HeLa, COS-1, Chinese hamster ovary, H9, NIH 3T3, and primary human keratinocytes and umbilical vein endothelial cells).
Experiments with enzyme conjugates prepared with either poly(L-lysine) or poly(L-arginine) in place of Tat resulted in surface-associated staining that was mostly trypsin accessi- In these experiments the development times of the chromogenic substrates for Tat-,Bgalactosidase were minutes to a few hours. When a (-galactosidase cDNA driven from a simian virus 40 promoter was transfected into cells, expression levels required several hours or overnight development, and staining never reached the levels reported here. This difference must reflect the relatively large levels of conjugate delivered into cells.
Since optimal uptake/long terminal repeat (LTR) activation of Tat required the presence of the lysosomotropic agent chloroquine to reduce protein degradation (19) , enzyme conjugate uptake was examined in the presence or absence of chloroquine. Equivalent staining patterns and intensities were observed over a range of chloroquine concentrations ( Fig. 1 b   and g ), and quantitative analysis of ,B-galactosidase activity in treated cells showed no more than a 2-fold increase in activity with chloroquine (data not shown). This is in comparison to Tat activation ofthe HIV-1 LTR, where chloroquine induction is 500-to 5000-fold.
To examine the in vivo biodistribution and potential delivery activity of this method, we injected Tat-3-galactosidase intravenously into mice. After sacrificed, tissues were harvested, and thin frozen sections were prepared for analysis. Histological staining showed very high tissue-associated activity in the liver (Fig. lk), spleen (Fig.  11) , and heart (Fig. lm) . Low but detectable staining was seen in skeletal muscle and lung, little or no staining was seen in the kidney, and none was seen in the brain. Analysis of stained sections showed that cells surrounding the blood vessels were labeled, with some penetration into surrounding cells and tissues visible. The red pulp in spleen was heavily stained, and there was evidence of Kupffer cells in liver and muscle cells in heart being labeled on examination 30 min after injection. The reasons for the tissue distribution observed are not clear but cannot reflect simply blood flow, given the relatively low level of staining seen in the lung/skeletal muscle, and may reflect qualitative or quantitative differences, or both, in the endothelium of these organs. With the control ,B-galactosidase, essentially no tissue staining was seen, with only trace levels evident in the spleen. When radiolabeled Tat-(1-72) peptide was administered intravenously, a tissue profile similar to that of Tat-,B-galactosidase was seen, except for very high levels in the kidney and a much shorter serum half-life for the peptide, presumably reflecting renal clearance (S.F., unpublished data).
Since histological analysis is complicated by the presence of active enzyme on the cell surface and within intracellular vesicular structures, we decided to use reporter cargo molecules whose activity would be translocation dependent. The toxin momordin has been used by Leamon and Low (15) as a reporter molecule to examine cellular uptake that was mediated by folate conjugation and utilized the folate receptor (16) . However, by analogy to ricin A chain (25) , it is not clear whether this molecule is nontoxic when added to cells simply because it lacks binding activity and whether it may retain a translocation function. This idea is supported by the cytotoxicity of momordin immunotoxins (26) . In contrast, the structure/function of PE has been studied in great detail (27, 28) , and the translocation activity of the native toxin has been localized to domain II. Therefore, we selected domain III of PE and also RNase A, since both are nontoxic when applied to cells and neither has any known binding or delivery activities. RNase is presumably toxic to cells because of nonspecific degradation of cellular RNA, while PE is known to ADP-ribosylate elongation factor 2, thus inactivating protein synthesis (27) and (ii) as either a growth factor for Kaposi's sarcoma-derived cells (29) or in the development of this cancer (30) . There are also several reports in the literature concerning the intracellular activity or localization, or both, of a number of growth factors including basic and acidic FGF, int2, and interleukin 1 (31) (32) (33) (34) . These factors either lack a recognizable signal sequence and yet can be secreted or, in some instances, are found in intracellular/nuclear locations. This raises the possibility that a family of factors, including the HIV-1 Tat protein, have gained the ability to enter/exit intact cells and that this function is part of their normal physiological action.
Recently, two laboratories have demonstrated that Tat binds to specific cell surface proteins, raising the possibility that delivery is receptor-mediated (35, 36 This system presents the opportunity to use macromolecular reagents to treat intact living cells and thus access the intracellular environment. Potential uses could include the delivery of peptide/protein inhibitors of intracellular enzymes or transcription factors or the delivery of peptide epitopes to stimulate class I major histocompatibility complex responses.
